Primer on Medical Genomics Part X: Gene Therapy

Russell, Stephen J.; Peng, Kah-Whye
November 2003
Mayo Clinic Proceedings;Nov2003, Vol. 78 Issue 11, p1370
Academic Journal
Gene therapy is defined as any therapeutic procedure in which genes are intentionally introduced into human somatic cells. Both preclinical and clinical gene therapy research have been progressing rapidly during the past 15 years; gene therapy is now a highly promising new modality for the treatment of numerous human disorders. Since the first clinical test of gene therapy in 1989, more than 600 gene therapy protocols have been approved, and more than 3000 patients have received gene therapy. However, at the time of writing this article, no gene therapy products have been approved for clinical use. This article explains the potential clinical scope of gene therapy and the underlying pharmacological principles, describes some of the major gene transfer systems (or vectors) that are used to deliver genes to their target sites, and discusses the various strategies for controlling expression of therapeutic transgenes. Safety issues regarding clinical use of gene therapy are explored, and the most important technical challenges facing this field of research are highlighted. This review should serve as an introduction to the subject of gene therapy for clinician investigators, physicians and medical scientists in training, practicing clinicians, and other students of medicine.


Related Articles

  • Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy. Breyer, Benjamin; Wei Jiang; Hongwei Cheng; Lan Zhou; Ronjon Paul; Tao Feng; Tong-Chuan He // Current Gene Therapy;Jul2001, Vol. 1 Issue 2, p149 

    Human gene therapy promises to change the practice of medicine by treating the causes of disease rather than the symptoms. Since the first clinical trial made its debut ten years ago, there are over 400 approved protocols in the United States alone, most of which have failed to show convincing...

  • Antiangiogenic gene therapy of cancer: recent developments. Tandle, Anita; Blazer III, Dan G.; Libutti, Steven K. // Journal of Translational Medicine;2004, Vol. 2, p22 

    With the role of angiogenesis in tumor growth and progression firmly established, considerable effort has been directed to antiangiogenic therapy as a new modality to treat human cancers. Antiangiogenic agents have recently received much widespread attention but strategies for their optimal use...

  • Potential Use of Gene Transfer in Athletic Performance Enhancement. Baoutina, Anna; Alexander, Ian E.; Rasko, John E. J.; Emslie, Kerry R. // Molecular Therapy;Oct2007, Vol. 15 Issue 10, p1751 

    After only a short history of three decades from concept to practice, gene therapy has recently been shown to have potential to treat serious human diseases. Despite this success, gene therapy remains in the realm of experimental medicine, and much additional preclinical and clinical study will...

  • The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Anson, Donald S. // Genetic Vaccines & Therapy;2004, Vol. 2, p9 

    Retroviral vector-mediated gene transfer has been central to the development of gene therapy. Retroviruses have several distinct advantages over other vectors, especially when permanent gene transfer is the preferred outcome. The most important advantage that retroviral vectors offer is their...

  • Next Generation Gene Therapy.  // Review of Ophthalmology;Jul2011, Vol. 18 Issue 7, p11 

    The article offers information on the extension of the University of Pennsylvania's approach to other types of blinding disorder through gene therapy that corrects an inherited type of blindness in the U.S. It highlights the use of laboratory animals and humans in performing clinical trials. The...

  • Gene therapy trial success.  // European Pharmaceutical Executive;Nov/Dec2005, p15 

    The article reports that Neurologix Inc.'s gene therapy clinical trial for patients with Parkinson's disease has shown positive results. The trial was the first study to use a viral vector for the treatment of an adult neurological disease. In the trial, the vector was injected into a specific...

  • Lentiviral vectors ready for prime-time. Kohn, Donald B. // Nature Biotechnology;Jan2007, Vol. 25 Issue 1, p65 

    The author comments on the paper presented on a clinical trial, in which an anti-HIV-1 gene is transferred and expressed using a lentiviral vector. The author suggests that the trial demonstrated safe gene delivery to patients' T-cells and that lentiviral vectors can be effectively used in...

  • Cardiac gene therapy in large animals: bridge from bench to bedside. Ishikawa, K; Tilemann, L; Ladage, D; Aguero, J; Leonardson, L; Fish, K; Kawase, Y // Gene Therapy;Jun2012, Vol. 19 Issue 6, p670 

    Several clinical trials are evaluating gene transfer as a therapeutic approach to treat cardiac diseases. Although it has just started on the path to clinical application, recent advances in gene delivery technologies with increasing knowledge of underlying mechanisms raise great expectations...

  • The AAV Vector Toolkit: Poised at the Clinical Crossroads. Asokan, Aravind; Schaffer, David V; Jude Samulski, R // Molecular Therapy;Apr2012, Vol. 20 Issue 4, p699 

    The discovery of naturally occurring adeno-associated virus (AAV) isolates in different animal species and the generation of engineered AAV strains using molecular genetics tools have yielded a versatile AAV vector toolkit. Promising results in preclinical animal models of human disease spurred...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics